STOK
Stoke Therapeutics, Inc.−$0.06 (0.23%) Thu · Closed $26.35
−$0.17 (0.65%) ☀ Pre-Market
Oct 30, 9:27 AM ET
About STOK
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Company
- Headquarters
- Bedford, MA
- Employees
- 170 (2026)
- Listed
- Jun 19, 2019
- Exchange
- Nasdaq
- Website
- stoketherapeutics.com
- SEC industry
- Pharmaceutical Preparations
- Cylvex sector
- Health Care · Pharmaceuticals
Pharmaceuticals
- Market cap #100 of 429
- P/B #92 of 396
Ranked highest first among stocks Cylvex covers.
- LLYEli Lilly and Company$1.22T+6.63%
- JNJJohnson & Johnson$662.5B+1.53%
- ABBVAbbVie Inc$513.9B+1.68%
- MRKMerck & Co Inc$361.0B+3.83%
- NVSNovartis AG$306.2B+3.22%
Financial summary
Related companies
About
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
From company filings and market data · Not investment advice
Price data
52W range and average volume from daily bars (unadjusted, last 252 sessions).
Financials
Consensus estimates
The information provided is for educational purposes only and does not constitute investment advice. Past performance does not guarantee future results.